It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 Title: Increased Long-Term Mortality in Patients Admitted to the Intensive Care Unit with
- 2 Health-Care Associated Pneumonia
- 3

4 **Running Title:** Long-Term Pneumonia Mortality

5

6 Authors:

- 7 Kristin R. Wise, MD
- 8 Assistant Professor of Medicine
- 9 Medical University of South Carolina, Division of Internal Medicine and Geriatrics
- 10
- 11 Jordan A. Kempker, MD, MSc
- 12 Pulmonary and Critical Care
- 13 Emory University, Department of Medicine, Division of Pulmonary and Critical Care Medicine
- 14 Atlanta, GA
- 15
- 16 Radu F. Neamu, MD
- 17 Attending Pulmonologist
- 18 Bryan Medical Center
- 19 Lincoln, NE
- 20
- 21 Ketino Kobaidze, MD, Ph.D (corresponding author)
- 22 Associate Professor of Medicine
- 23 550 Peachtree Street, Atlanta, GA 30308
- 24 Cell: 404 840 4395
- 25 E- mail: kkobaid@emory.edu
- 26 Emory University, Department of Medicine, Division of Hospital Medicine

It is made available under a CC-BY-NC-ND 4.0 International license .

- 27 Atlanta, GA
- 28 An institution where work was performed: Emory University, Atlanta, GA
- 29 **Funding:** None for this current study. The creation of the original prospective cohort database
- 30 used in this study was funded by grants from the Carlyle Fraser Heart Center and the
- 31 Department of Medicine at Emory University. The funders had no role in the original study
- design, data collection, data analysis, and interpretation, or manuscript writing.
- 33 **Keywords:** Healthcare-Associated Infection; Pneumonia; Mortality; Health Services Research;
- 34 Critical Illness
- 35 Acknowledgments: The authors have neither financial interests nor conflicts of interest to
- 36 disclose.

It is made available under a CC-BY-NC-ND 4.0 International license .

37 Summary of Key Points:

39	•	The American Thoracic Society (ATS) and the Infectious Diseases Society of America
40		(IDSA) developed and periodically update guidelines for the diagnosis and management of
41		community-acquired and nosocomial pneumonia based on the patient-care setting in which
42		pneumonia evolved. ATS/IDSA provides guidelines for empiric antibiotic choices based on
43		the category of pneumonia that is diagnosed.
44	•	Pneumonia is a significant cause of mortality in the United States and when combined with
45		influenza ranks as the eighth leading cause of death nationwide yet little is known about the
46		mortality of critically ill patients with pneumonia that require admission to a medical intensive
47		care unit (ICU).
48	•	Our findings suggest that older age, higher severity of illness at ICU admission, and chronic
49		comorbid illnesses are the main contributors to long-term mortality from pneumonia requiring
50		ICU admission.
51	•	In this cohort, we found an independent association between increased mortality and
52		admission from the general hospital ward rather than directly from the emergency
53		department.
54	•	Our study did not demonstrate that initial guideline-based antibiotic therapy was associated
55		with a reduction in short-term mortality; however, it did demonstrate a high prevalence of
56		resistant pathogens in HCAP/HAP patients, which reflects ATS/IDSA guideline expectations.

It is made available under a CC-BY-NC-ND 4.0 International license .

57 **Background:** Pneumonia is a leading cause of death in the United States. Guidelines for its 58 diagnosis and management are periodically updated, but long-term mortality in critically ill 59 patients has not been well studied.

60 **Objective:** To determine differences in one-year mortality between patients with community-61 acquired pneumonia (CAP) and healthcare-associated pneumonia or hospital-acquired 62 pneumonia (HCAP/HAP).

Methods: A retrospective multivariate analysis of a prospective cohort study that included all
 patients admitted to a single-center medical intensive care unit (ICU) from October 1, 2007,
 through September 30, 2008, with a diagnosis of pneumonia.

Results: There were 181 patients admitted to the medical ICU with a diagnosis of pneumonia, 66 67 58.0% with HCAP/HAP and 42.0% with CAP. Those with HCAP/HAP had an older age 68 distribution and higher proportions of cardiovascular (79.1% vs. 63.2%, P=0.02) and neurological (36.2% vs. 18.4%, P=0.01) comorbidities. The HCAP/HAP patients demonstrated 69 70 an increased risk of death within one a year in the unadjusted analysis (HR 1.6, 95% CI 1.1-2.2, 71 P=0.01) that did not remain significant in the multivariate analysis (HR 1.3, 95% CI 0.80-2.10. 72 P=0.29) when adjusting for simplified acute physiology score (SAPS) II score, age category, 73 source of admission and a history of diabetes mellitus, neurological disease or malignancy.

Conclusion: Compared to patients admitted to a medical ICU with CAP, those with HCAP/HAP
 had a higher one-year mortality that is accounted for by the increased co-morbidities associated
 with a HCAP/HAP diagnosis.

It is made available under a CC-BY-NC-ND 4.0 International license .

78 INTRODUCTION

79 Pneumonia is a significant cause of mortality in the United States (US) and when combined with influenza ranks as the eighth leading cause of death nationwide, causing an 80 81 estimated 50,000 deaths a year (1). In an effort to confront this public health concern, the 82 American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) developed and periodically update guidelines for the diagnosis and management of community-83 acquired and nosocomial pneumonias. In 2005, these guidelines outlined a different approach 84 85 to what was previously known as nosocomial pneumonia, dividing it into three categories based 86 on the patient-care setting in which the pneumonia evolved (2). These three categories are healthcare-associated pneumonia (HCAP), hospital acquired pneumonia (HAP) and ventilator-87 associated pneumonia. Similarly, specific guidelines were published in 2007 to help clinicians 88 89 with the management of community acquired pneumonia (CAP) (3).

90 Since publication, these guidelines have spurred research into the efficacy and safety of 91 their treatment recommendations for each pneumonia class as well as their ability to identify 92 patients at risk for drug-resistant pathogens and higher mortality (4-26). In regards to the latter, 93 six studies have examined mortality differences among the different pneumonia types in 94 hospitalized patients and have shown heterogeneous results (8, 11, 12, 14, 18, 22). Among 95 these studies, there is a paucity of data specifically examining critically ill patients and long-term 96 mortality. To our knowledge, only one recent study has examined this question, demonstrating 97 that pneumonia type for patients admitted to the intensive care unit (ICU) was associated with 98 long term mortality but not short term mortality (12). Given the high incidence of this morbid disease, further information is needed regarding the outcomes of the of the various types of 99 pneumonias presenting to the ICU to better identify the burden of disease they each represent 100 101 to the community and to help prognosticate for individual patients. In this study, we compared 102 the one-year survival among patients admitted to the medical ICU with CAP, HCAP, and HAP 103 and examined the patient characteristics that are associated with mortality.

It is made available under a CC-BY-NC-ND 4.0 International license .

104

105 MATERIALS AND METHODS

106 Study population

This study is a retrospective analysis of a previously collected prospective cohort of patients admitted to the medical ICU from October 1, 2007, through September 30, 2008, at a single center 511-bed urban, an academic hospital in Atlanta, Georgia. The details regarding the patient population in the above-mentioned database are described elsewhere (27). The study proposal was approved by the Emory University Institutional Review Board.

112 All adult patients admitted to the ICU within the above period with a diagnosis of pneumonia were included in the study. We excluded patients admitted to the medical ICU with 113 ventilator-associated pneumonia (which generally encompassed patients with tracheostomies 114 115 from ventilator weaning facilities) and those who did not meet criteria for pneumonia based on 116 documented evidence of a new radiographic infiltrate plus documentation of at least two of the 117 following signs or symptoms: 1) white blood cell count >10,000/ml or <4,000/ml; 2) temperature 118 > 38.3° or < 35° Celsius; 3) purulent secretions from the lower respiratory tract; or 4) new-onset 119 or worsening of dyspnea, oxygen requirements or altered mental status.

120 Data Sources and Variables

121 All data were gathered from the electronic medical record by study investigators and 122 entered into an Excel spreadsheet (Microsoft Corporation). The primary variable of interest was the pneumonia type on admission to the medical ICU. Diagnoses of CAP, HCAP, and HAP were 123 124 determined by study investigators based on documented evidence of criteria according to the 2005 ATS/IDSA guideline definitions (2). Furthermore, the diagnosis of HAP required the 125 documented absence of an infiltrates on a chest x-ray at the initial hospital admission with the 126 127 development of a new infiltrate upon transfer to the medical ICU. The primary outcome of interest was one-year all-cause mortality, which was determined by linking patients to their 128 corresponding death records with the US Social Security database. 129

It is made available under a CC-BY-NC-ND 4.0 International license .

130 Patient characteristics collected from the electronic medical record included age, gender, 131 race (self-identified), medical co-morbidities, and source of ICU admission. The severity of 132 illness scores, acute physiology, and chronic health evaluation (APACHE) II and simplified acute physiology score (SAPS) II, were calculated using the standard formula with physiologic 133 134 variables from the time of the ICU admission. For microbiologic data, we recorded the results of the first blood cultures collected during the period from 6 hours before arrival to the ICU until 3 135 136 days after. To capture the etiology for pneumonia, all lower respiratory tract (LRT) cultures 137 obtained during the first 5 days after ICU admission were recorded. An LRT culture was defined 138 as a tracheal aspirate, bronchoalveolar lavage (BAL), bronchial wash, protected brush specimen, or mini-BAL. A multi-drug resistant (MDR) gram-negative pathogen was defined as 139 one with documented decreased susceptibility to at least two of the antibiotic classes 140 141 recommended for treating pneumonia as delineated by the 2005 ATS/IDSA guidelines (2).

142 For treatment variables, we recorded all antibiotics administered during the period of 12 hours before arrival in the ICU through ICU discharge. Antibiotic appropriateness was 143 determined by antibiotics given at ICU admission and deemed inappropriate if: 1) they did not 144 145 include the recommended antibiotic classes for CAP, HCAP, and HAP in the 2005 and 2007 146 ATS/IDSA guidelines, including double coverage for *Pseudomonas aeruginosa* for HCAP and HAP and atypical coverage for CAP, or 2) they included antibiotics outside of those 147 148 recommended for respective pneumonia (i.e., using HCAP coverage for CAP). Other treatment variables collected include the use and duration of noninvasive or invasive mechanical 149 150 ventilation. Outcomes recorded included ICU and hospital length of stay and mortality.

151 Statistical Analysis

All data analyses were performed using SAS 9.3 (SAS Institute Inc. Cary, NC) statistical software. We initially intended to compare CAP, HAP, and HCAP as separate categories, but only 15 (8.0%) subjects had HAP. Therefore, HAP and HCAP were combined for analysis and are referred to as HCAP/HAP in our study. For the bivariate analyses, categorical variables

It is made available under a CC-BY-NC-ND 4.0 International license .

156 were compared with a chi-square test or Fisher's exact test. Continuous variables with a normal 157 distribution were compared with a two-tailed t-test. Continuous variables with a non-normal 158 distribution were compared using the Wilcoxon Ranked Sum test. The model for the multivariate 159 analysis was constructed using the covariate selection method described by Hosmer and 160 Lemeshow and is briefly described here (28). Covariates were initially selected for model inclusion if they were associated with both the primary outcome and exposure at a p-value < 161 162 0.25 in the bivariate analyses. Then, covariates were retained in the model for a p-value < 0.10163 or if upon removal from the model, the pneumonia classification parameter estimate did not 164 change by \geq 20%. Then each covariate from the entire dataset was entered into this reduced model and retained if they changed the pneumonia classification parameter estimate by \geq 20%. 165 Final p-values of <0.05 were considered statistically significant. 166

167

168 **RESULTS**

169 Patient Characteristics

170 During the study period, 1,357 patients were admitted to the medical ICU of which 181 171 (13.3%) carried a diagnosis of pneumonia. There were 105 (58.0%) patients with HCAP/HAP 172 and 76 (42.0%) with CAP. Table 1 compares the baseline demographics, preexisting comorbidities, and clinical stay characteristics of CAP and HCAP/HAP patients. When 173 174 compared to CAP, patients with HCAP/HAP had a significantly older age distribution and higher proportions of cardiovascular (79.1% vs. 63.2%, P=0.02) and neurological (36.2% vs. 18.4%, 175 176 P=0.01) comorbidities. There were trends towards higher APACHE II and SAPS II scores in HCAP/HAP patients (23.7 vs. 21.8, P=0.07 and 45.4 vs. 41.5, P=0.08, respectively). 177

178 Main Findings

The one-year survival for critically ill pneumonia patients and their characteristics associated with mortality are shown in Table 2 and their Cox proportional survival curves are depicted in Figure 1. The one-year crude mortality of HCAP/HAP and CAP patients was 62.0%

It is made available under a CC-BY-NC-ND 4.0 International license .

182 and 34.0%, respectively. HCAP/HAP patients had an increased risk of death within one year in 183 the unadjusted analysis (HR 1.6, 95% CI 1.1-2.2, P=0.01). This finding did not remain 184 statistically significant in the multivariate analysis (HR 1.3, 95% CI 0.8-2.1, P=0.29) when adjusting for SAPS II score, age category, source of ICU admission, and preexisting conditions 185 of diabetes mellitus, neurological disease or malignancy (Table 2). We performed a secondary, 186 187 exploratory analysis examining mortality at different time points, showing an increase in 188 unadjusted mortality among HCAP/HAP patients at 60 days, but not at 30 or 90 days (Table 3). 189 We ran our multivariable model with the 60-day outcome and again HCAP/HAP did not remain a 190 significant risk factor for mortality.

191 Microbiology of Pneumonias and Antibiotic Treatment

Cultures were not performed in 5.7% and 5.3% of HCAP/HAP and CAP patients, 192 193 respectively. The first culture obtained was a blood culture in the majority of both HCAP/HAP 194 (84.8%) and CAP (81.6%) patients. Lower respiratory cultures were performed in 32.4% of 195 HCAP/HAP and 27.6% of CAP patients. Figure 2 summarizes the microbiology of the 196 pneumonias in the study group. Blood and respiratory tract cultures remained negative in 52.6% 197 of CAP patients and 43.8% of HCAP/HAP patients. Methicillin-resistant Staphylococcus aureus 198 (MRSA) and MDR gram-negative bacilli were not cultured among the CAP patients while these 199 organisms comprised the infectious agent in 6.7% and 3.8% of the HCAP/HAP patients, 200 respectively.

When compared to HCAP/HAP patients, those with CAP were more likely to have the appropriate initial antibiotic therapy at admission to the ICU (38.2% vs. 17.1%, P<0.01) as shown in Table 1. However, appropriate antibiotics did not adid not affect one-year mortality, with 27.1% of the survivors and 25.0% of non-survivors receiving appropriate antibiotics (P=0.75).

206 Other Outcomes

It is made available under a CC-BY-NC-ND 4.0 International license .

Invasive mechanical ventilation was required in 38.1% of the CAP patients and 38.1% of the HCAP/HAP patients (Table 1). There were no significant differences in the use of noninvasive positive pressure ventilation or ICU or hospital length of stay between the two pneumonia groups.

211

212 **DISCUSSION**

213 This study compares the characteristics and outcomes between patients admitted to a single-center medical ICU with a diagnosis of CAP or HCAP/HAP over one year. Patients with 214 215 HCAP/HAP were older with more medical comorbidities and more resistant pathogens. While 216 our study identified that the HCAP/HAP patients had an increased, unadjusted one-year 217 mortality when compared to CAP, this finding did not persist when adjusted for SAPS II score, 218 age, source of ICU admission and preexisting diabetes mellitus, neurological disease, or 219 malignancy. These findings suggest that older age, higher severity of illness at ICU admission, 220 and chronic comorbid illnesses are the main contributors to long-term mortality from 221 pneumonias requiring ICU admission.

222 We compared our mortality findings with the existing literature, which focuses mostly on 223 short-term mortality. To date, we know of only one study that has examined long-term mortality by pneumonia type in patients admitted to ICU. This study demonstrated no difference in 224 225 adjusted short-term mortality but showed a higher unadjusted one-year mortality among patients with HAP (12). This may be similar to our unadjusted findings of an increased risk of death 226 227 within one year for HCAP/HAP patients that did not remain statistically significant in our 228 multivariate analysis. While five studies have found that HCAP carries higher unadjusted 229 mortality, this association remained in only one of the three studies that adjusted for 230 confounders. Not surprisingly, these data have also shown that patients with HCAP are older with more severe chronic comorbidities and often present with more severe illness (8, 11, 14, 231 18, 22). In regards to the effects of comorbid illnesses, one study examining the long-term 232

It is made available under a CC-BY-NC-ND 4.0 International license .

mortality of patients hospitalized with CAP also found that older age, cerebrovascular disease, and cardiovascular disease were associated with increased mortality (29). Overall, the sum of these data, combined with our study results, suggest that the current pneumonia classification is not an independent risk factor for mortality but rather a marker of more chronic and severe illness.

238 In addition to our main results, our study identified several other interesting findings. In 239 this cohort, we found an independent association between increased mortality and admission 240 from the general hospital ward rather than directly from the emergency department. A similar 241 association was found in one study that examined the source of ICU admission for patients with septic shock (30). In that study, in comparison to patients admitted from the general ward, those 242 from the emergency department had lower in-hospital mortality, less mechanical ventilation 243 244 utilization, and shorter times to achieving $ScVO_2$ goals (30). As our study was not designed to 245 compare the differences between patients admitted to the medical ICU from these two sources, 246 we can only speculate as to whether treatment in the emergency department was protective or 247 whether admission from the hospital ward was confounded by co-morbid and concurrent illness.

248 Finally, our study did not demonstrate that initial guideline-based antibiotic therapy was 249 associated with a reduction in short-term mortality; however, it did demonstrate a high 250 prevalence of resistant pathogens in HCAP/HAP patients, which reflects ATS/IDSA guideline 251 expectations. There were no cultures positive for MDR gram-negative bacilli or MRSA among ICU patients with CAP while these organisms were present in 10.5% of HCAP/HAP patients. 252 253 The existing published literature demonstrates varying conclusions with only a portion of the 254 studies showing a high prevalence of *Pseudomonas aueroginosa* and MRSA in both HCAP and 255 CAP patients (4, 19, 25, 26, 31). Such discrepancies may explain the inconsistent reported 256 results on the association between guideline-based antibiotic therapy and mortality (7, 10, 13, 257 15-17, 23, 24). Other investigators have sought alternate means to identify those at higher risk

It is made available under a CC-BY-NC-ND 4.0 International license .

of resistant pulmonary pathogens although significant research is still needed in this area (6, 9,
20, 21).

260 There are limitations to the present study that must be noted. This is a single-center 261 study and as the microbiology of pneumonia may vary according to the setting, our results may 262 not be generalizable. Although the initial cohort was captured prospectively, study investigators determined the diagnoses of pneumonia on retrospective chart review. While the use of specific 263 264 criteria to define the various pneumonia types increases internal validity, there may be 265 confounding factors in original medical documentation that led to misclassification errors in the 266 study. Furthermore, the retrospective design may have limited an aggressive approach to the microbiologic diagnosis of pneumonia, resulting in a lower proportion of patients with a LRT 267 268 culture. Despite these limitations, this study continues research in an important area and is able 269 to provide additional data regarding the clinical characteristics, microbiologic findings and 270 mortality outcomes of patients admitted to ICU with a diagnosis of pneumonia obtained from a 271 realistic practice setting.

272

273 CONCLUSION

This study demonstrates higher one-year mortality among patients admitted to a medical ICU with HCAP/HAP compared to those admitted with CAP that is likely accounted for by the increased co-morbidities associated with a HCAP/HAP diagnosis. Further evidence is needed to distinguish the true, and likely evolving, microbiologic relevance of the distinction between HCAP/HAP and CAP to guide future treatment recommendations.

It is made available under a CC-BY-NC-ND 4.0 International license .

279 **References**

Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat
 Rep. 2011;59(10):1-126.

282 2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the 283 management of adults with hospital-acquired, ventilator-associated, and healthcare-associated 284 pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.
 Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the
 management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27 72.

Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence,
 risk, and prognosis. Arch Intern Med. 2002;162(16):1849-58.

5. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, et al. Guidelineconcordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. 2011;38(4):878-87.

Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease,
 and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial
 pneumonia. Curr Opin Infect Dis. 2009;22(3):316-25.

Capelastegui A, Espana PP, Quintana JM, Gorordo I, Ortega M, Idoiaga I, et al.
Improvement of process-of-care and outcomes after implementing a guideline for the
management of community-acquired pneumonia: a controlled before-and-after design study.
Clin Infect Dis. 2004;39(7):955-63.

Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al.
 Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a
 UK cohort study. Clin Infect Dis. 2011;53(2):107-13.

It is made available under a CC-BY-NC-ND 4.0 International license .

9. El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drugresistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis. 2004;39(4):47480.

Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU, et al.
Guideline-concordant antibiotic use and survival among patients with community-acquired
pneumonia admitted to the intensive care unit. Clin Ther. 2010;32(2):293-9.

Grenier C, Pépin J, Nault V, Howson J, Fournier X, Poirier MS, et al. Impact of guideline consistent therapy on outcome of patients with healthcare-associated and community-acquired
 pneumonia. J Antimicrob Chemother. 2011;66(7):1617-24.

12. Karhu J, Ala-Kokko TI, Ylipalosaari P, Ohtonen P, Laurila JJ, Syrjälä H. Hospital and long-term outcomes of ICU-treated severe community- and hospital-acquired, and ventilatorassociated pneumonia patients. Acta Anaesthesiol Scand. 2011;55(10):1254-60.

13. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, et al. Implementation
of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an
observational, multicentre cohort study. Lancet Infect Dis. 2011;11(3):181-9.

14. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culturepositive pneumonia. Chest. 2005;128(6):3854-62.

15. Lancaster JW, Lawrence KR, Fong JJ, Doron SI, Garpestad E, Nasraway SA, et al.
 Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of
 antibiotic therapy and patient outcomes. Pharmacotherapy. 2008;28(7):852-62.

Madaras-Kelly KJ, Remington RE, Sloan KL, Fan VS. Guideline-based antibiotics and
 mortality in healthcare-associated pneumonia. J Gen Intern Med. 2012;27(7):845-52.

McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy
and reduced mortality and length of stay in adults with community-acquired pneumonia: playing
by the rules. Arch Intern Med. 2009;169(16):1525-31.

It is made available under a CC-BY-NC-ND 4.0 International license .

Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated
pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents
Chemother. 2007;51(10):3568-73.

19. Quartin AA, Scerpella EG, Puttagunta S, Kett DH. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilatorassociated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC infectious diseases. 2013;13:561.

Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibioticresistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med.
2008;168(20):2205-10.

Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al. Validation of a
clinical score for assessing the risk of resistant pathogens in patients with pneumonia
presenting to the emergency department. Clin Infect Dis. 2012;54(2):193-8.

22. Venditti M, Falcone M, Corrao S, Licata G, Serra P, Medicine SGotlSol. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150(1):19-26.

Webb BJ, Dangerfield BS, Pasha JS, Agrwal N, Vikram HR. Guideline-concordant
antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. Respir Med.
2012;106(11):1606-12.

Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy
 escalation and hospital mortality among patients with health-care-associated pneumonia: a
 single-center experience. Chest. 2008;134(5):963-8.

25. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not
 accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin
 Infect Dis. 2014;58(3):330-9.

It is made available under a CC-BY-NC-ND 4.0 International license .

26. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2013;57(10):1373-83.

27. Wise KR, Akopov VA, Williams BR, Ido MS, Leeper KV, Dressler DD. Hospitalists and intensivists in the medical ICU: a prospective observational study comparing mortality and length of stay between two staffing models. J Hosp Med. 2012;7(3):183-9.

Hosmer D, Lemeshow S, May S. Applied survival analysis: regression modeling of time to-event data. Hoboken, NJ: Wiley-Interscience; 2008.

Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with
 community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169(8):910-4.

367 30. Wang Z, Schorr C, Hunter K, Dellinger RP. Contrasting treatment and outcomes of
368 septic shock: presentation on hospital floors versus emergency department. Chin Med J (Engl).
369 2010;123(24):3550-3.

370 31. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-

associated bacterial pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S81-7.

Table 1. Patient Characteristics by Pneumonia Type in Adults Admitted to a Medical Intensive

374 Care Unit.

Variable	САР	HCAP/HAP	P value
	n = 76	n = 105	
Demographic Characteristics			
Age, years, n (%)			0.01
< 35	7 (9.2)	8 (7.6)	
35-49	21 (27.6)	11 (10.5)	
50-64	17 (22.4)	44 (41.9)	
65-80	18 (23.7)	25 (23.8)	
> 80	13 (17.1)	17 (16.2)	
Gender, female, n (%)	33 (43.4)	56 (53.3)	0.19
Race, black, n (%)	54 (71.1)	79 (75.2)	0.81
Preexisting Comorbidities			
Past Medical History, n (%)			
Cardiovascular Disease	48 (63.2)	83 (79.1)	0.02
Pulmonary Disease	24 (31.6)	45 (42.9)	0.12
Diabetes Mellitus	24 (31.6)	45 (42.9)	0.12
Chronic Kidney Disease	17 (22.4)	32 (30.5)	0.23
Neurological Disease	14 (18.4)	38 (36.2)	0.01
Malignancy	12 (15.8)	18 (17.1)	0.81
Human Immunodeficiency Virus	13 (17.1)	15 (14.3)	0.60

It is made available under a CC-BY-NC-ND 4.0 International license .

Gastroenterological Disease	13 (17.1)	17 (16.2)	0.87
Morbid Obesity (BMI ≥40)	4 (5.3)	8 (7.6)	0.53
Immunocompromise	5 (6.6)	5 (4.8)	0.60
Clinical Stay Characteristics			
Location before ICU Transfer, n (%)			0.06
Emergency Department	53 (69.7)	59 (56.2)	
General Hospital Ward	23 (30.3)	46 (43.8)	
APACHE II Score, mean ±SD	21.8 ± 6.9	23.7 ± 7.2	0.07
SAPS II Score, mean ±SD	41.5 ± 15.1	45.4 ± 14.3	0.08
Appropriate Empiric Antibiotics, n (%)	29 (38.2)	18 (17.1)	<0.01
Lower Respiratory Culture Obtained, n (%)	21 (27.6)	34 (32.4)	0.49
MDR Organism Identified, n (%)	2 (2.6)	12 (11.4)	0.05
Endotracheal Intubation, n (%)	29 (38.1)	40 (38.1)	1.0
Noninvasive Ventilation, n (%)	23 (30.3)	34 (32.4)	0.76
ICU Length of Stay, median days (IQR)	3 (2.0-7.0)	4 (2.0-8.0)	0.41
Hospital Length of Stay, median days (IQR)	9 (5.7 -13.6)	9.8 (5.3-19.7)	0.35

APACHE, acute physiology and chronic health evaluation; BMI, body mass index; CAP, communityacquired pneumonia; HCAP/HAP, healthcare-associated/hospital-acquired pneumonia; ICU, intensive care unit; IQR, Inter-quartile range; SAPS, simplified acute physiology score; MSSA, Methicillin-sensitive Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; MDR, Multi-drug resistant.

- 380 Table 2. Multivariate Cox Proportional Hazards Model for Time from Intensive Care Unit
- 381 Admission to Death within One Year Among Patients Admitted to a Medical Intensive Care Unit
- with Pneumonia, N = 181, Likelihood Ratio Test p < 0.0001.

Variable	Hazard Ratio (95% CI)	P value
HCAP/HAP vs. CAP	1.30 (0.80-2.10)	0.29
SAPS II Score	1.02 (1.01-1.04)	<0.01
Admitted From General Hospital Ward vs. ED	1.66 (1.05-2.49)	0.03
Age Category		
< 35	Referent	
35-49	0.81 (0.28-2.40)	0.70
50-64	1.04 (0.39-2.80)	0.94
65-80	1.54 (0.57-4.17)	0.39
> 80	1.92 (0.69-5.39)	0.21
Preexisting Comorbidities		
Neurological Disease	0.98 (0.59-1.62)	0.94
Diabetes Mellitus	0.72 (0.40-1.12)	0.14
Malignancy	2.70 (1.61-4.51)	<0.01

383 CAP, community-acquired pneumonia; ED, emergency department; HCAP/HAP, healthcare-

associated/hospital-acquired pneumonia; SAPS, simplified acute physiology score.

385 **Table 3**, Exploratory Analysis of Different Mortality Endpoints in Patients with Pneumonia

Morta	lity CAP Mortality	HCAP/HAP Mortality	Unadjusted RR (95%CI)	P value
Endpo	oint n (%)	n (%)	HCAP/HAP v. CAP	
ICU	7 (9.2)	14 (13.3)	1.3 (0.7-2.4)	0.39
30-Day	/ 17 (22.4)	33 (31.4)	1.3 (0.9-2.1)	0.18
60-Day	/ 17 (22.4)	43 (41.0)	1.7 (1.1-2.7)	0.09
90-Day	/ 23 (30.3)	46 (43.8)	1.4 (1.0-2.1)	0.06
One Y	ear 32 (42.1)	64 (61.0)	1.6 (1.1-2.2)	0.01

Admitted to the Intensive Care Unit by Pneumonia Type.

- 387 CAP, community-acquired pneumonia; HCAP/HAP, healthcare-associated/hospital-acquired
- 388 pneumonia; ICU, intensive care unit.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Cox Proportional Survival Curves for Mortality From Intensive Care Unit (ICU) 391 392 Admission to One Year Among Patients with Pneumonia Admitted to a Medical ICU. Stratified by Pneumonia Type and Adjusted for Simplified Acute Physiology Score (SAPS) II, Location 393 394 Before Admission, Age Category and Preexisting of Neurological Disease, Diabetes Mellitus and Malignancy. N = 181. 395

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2. Pathogens Detected in Respiratory and Blood Cultures According to Pneumonia Type. The other category included yeast, nontuberculous mycobacterial species, unidentified gram positive cocci and pneumocystis jirovecii in decreasing order of frequency. CAP, community-acquired pneumonia; HCAP/HAP, healthcare-associated/hospital-acquired pneumonia; MSSA, Methicillin-sensitive Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; MDR, Multi-drug resistant.